MENU

New Technologies for Accessible, Durable and Broadly Protective Coronavirus Vaccines

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • CEO, IDRI; Clinical Professor of Medicine and Global Health, University of Washington; Affiliate Professor, Vaccine and Infectious Disease Division, Fred Hutch Cancer Research Center
    Biography

      Corey Casper is the Chief Executive Officer at the Infectious Disease Research Institute (IDRI). At IDRI, Dr. Casper oversees a portfolio of vaccines, therapeutics, and diagnostics that provide comprehensive solutions to global health problems. These include immune-enhancing adjuvant formulations that enable strong, safe and durable vaccines, a novel RNA vaccine platform for the prevention of pandemic / emerging viruses, and products for the treatment and prevention of cancer in low- and middle-income countries.



      Dr. Casper received his medical degree from Cornell University, and completed Residency in Internal Medicine at the University of California – San Francisco and Fellowship in Infectious Disease at the University of Washington, where he also earned a Masters of Public Health. His research focuses on the relationship between infectious diseases, immunity and cancer. He has authored more than 125 peer-reviewed publications, and has received funding as the Principal Investigator of more than 100 million dollars in NIH and industry-sponsored studies. Key contributions to science include the development and deployment of diagnostic assays for tumor viruses, design and execution of Phase 1 and Phase 2 vaccine trials, leadership of multi-phased international immunotherapy clinical trials from conception to publication culminating in FDA licensure, epidemiologic and cost effectiveness analyses, and translational studies of the virologic and immunologic basis of infectious diseases and cancer.



      Dr. Casper is also a committed educator and clinician. He is a Clinical Professor of Medicine and Global Health at the University of Washington (where he is the Associate Director of the Center for AIDS Research) and an Affiliate Professor in the Vaccine and Infectious Disease Division at the Fred Hutchinson Cancer Research Center (where he served as Associate Cancer Center Director and Founding Head of the Global Oncology Program). Dr Casper cares for patients with infectious diseases and cancer at the Seattle Cancer Care Alliance and the University of Washington Medical Center.


    Abstract

    Over a year into the COVID-19 pandemic, key vulnerable populations in the United States and across the world lack access to effective vaccines. IDRI has developed technology that addresses some of the most important unmet vaccine needs. Our technology is proven to make RNA vaccines stable at room temperature for nearly a year, enables safe and highly-effective protein vaccines that provide durable protection against current and future COVID mutations, and allows for the advancement of vaccines that will be suitable for young children. These discoveries can help support the global effort to end COVID-19 and reduce the burden of the inevitable next pandemic.

    Learning Objectives:

    1. To understand limitations in current vaccines against SARS-CoV-2 that compromise universal access, durability and broadly protective immune responses

    2. To become familiar with the technology behind self-amplifying / self-adjuvanting RNA vaccines delivered by a novel nanostructured lipid carrier, which generate potent immune responses and are stable at room temperature for nearly a year

    3. To explore the use of vaccine adjuvant formulations as a method to generate durable and broadly-protective immune responses against coronaviruses.


    Show Resources
    You May Also Like
    DEC 03, 2020 4:30 PM PST
    C.E. CREDITS
    DEC 03, 2020 4:30 PM PST
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    MAY 11, 2021 10:00 AM PDT
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    APR 01, 2021 8:00 AM PDT
    C.E. CREDITS
    APR 01, 2021 8:00 AM PDT
    Date: April 01, 2021 Time: 8:00am (PST), 11:00am (EST) Generating therapeutic antibodies is far more challenging than obtaining antibodies that merely recognize their targets. Engineering po...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    FEB 24, 2021 10:00 AM PST
    C.E. CREDITS
    FEB 24, 2021 10:00 AM PST
    DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
    Loading Comments...
    Show Resources
    Attendees
    • See more